Skip to main content

Table 1 Characteristics of studies included in the analyses

From: Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

Author, year Design Vaccination status£* Vaccine strain Number of HI titre intervals$ Drop-out rate#
   Vaccinated Unvaccinated Unknown    
Bell et al., 1957 [32] Challenge 32 (14) -   A 3 > 10%
Clark et al., 1983a [33] Challenge 49 (7) 23 (16)   A 6 ≤ 10%
Clark et al., 1983b [34] Challenge 39 (6) 58 (23)   A 5 ≤ 10%
Dowdle et al., 1973 [35] Trial 227 (90)    A 4 ≤ 10%
Eaton and Meiklejohn, 1945 [36] Trial 94 (4) 145 (9)   A(Olson) 5 ≤ 10%
   94 (9) 145 (4)   A(PR8)   
   94 (9) 145 (4)   B   
Evans, 1975 [37] Cohort 696 (262) -   A 5 NA
   346 (47)    B   
Farnik and Bruj, 1966 [38] Cohort - 248 (52)   A 5 ≤ 10%
Fox et al., 1982 [39] Cohort - - 222 (13) A(H1N1) 4 ≤ 10%
     343 (98) A(H3N2) 3  
     140 (28) B 3  
Goodeve et al., 1983 [40] Challenge 97 (9) 23 (15)   B 6 ≤ 10%
Greenberg, Couch and Kasel, 1974 [41] Cohort - 212 (97)   A 5 ≤ 10%
Hirota et al., 1997 [24] Trial 84 (4) 118 (9)   A(H1N1) 3 ≤ 10%
   84 (4) 118 (9)   A(H3N2)   
   84 (4) 118 (9)   B   
Hobson et al., 1972 [5] Challenge    106 (20) A(Field Trial) 9 NA
     345 (166) A(HK Salisbury)   
   - - 119 (62) A(Pre-1968)   
     462 (135) B   
Meiklejohn et al., 1952 [42] Trial - 101 (5)   A 6 > 10%
Potter et al., 1977 [43] Challenge 134 (26) -   A 6 ≤ 10%
Salk et al., 1945 [8] Trial 82 (2) 246 (21)   A(Weiss) 10 > 10%
   82 (2) 144 (12)   A(PR8)   
  1. *: Number of observations (number of influenza cases)
  2. $. Number of reported intervals on pre-season HI titres.
  3. £ Vaccination performed just before exposure
  4. # Number of subjects analyzed/Number of subjects included in the analysis